Public health and safety; Uniform Controlled Dangerous Substances Act; process for obtaining informed consent from patients; emergency.
Impact
HB1082 would bring significant changes to state laws governing the prescription of opioids. It limits the initial prescription for acute pain to a maximum seven-day supply and mandates the evaluation of patients’ prior treatment histories and potential risks of opioid use. By requiring practitioners to discuss the dangers of addiction and the possibility of alternative treatments, the bill aims to make prescribing practices safer and more responsible. Additionally, the creation of a patient-provider agreement for ongoing opioid therapy will ensure continuous monitoring of patients, which can aid in identifying potential misuse early.
Summary
House Bill 1082 aims to amend the Uniform Controlled Dangerous Substances Act in Oklahoma, specifically addressing the prescription and management of opioid drugs. It establishes clear guidelines for practitioners regarding the issuance of opioid prescriptions, including restrictions on initial quantities and the necessity of informed consent processes for patients requiring opioid therapy for extended durations. The bill also requires practitioners to document their assessments and treatment plans for pain management comprehensively. These measures intend to combat opioid misuse while ensuring that patients in need of pain relief receive appropriate care.
Sentiment
The general sentiment around HB1082 appears to be cautiously optimistic, with supporters advocating for the bill as a necessary step in the state’s response to the opioid crisis. Many healthcare professionals recognize the need for stricter guidelines to promote patient safety and reduce the risk of addiction. However, there are concerns among some practitioners regarding the potential bureaucratic burden that these new requirements may impose, including extensive documentation and ensuring compliance with the informed consent process.
Contention
Notable points of contention include the balance between managing opioid prescriptions and ensuring adequate pain relief for patients. Some stakeholders fear that overly stringent regulations could inadvertently hinder access to necessary medications for patients with chronic pain conditions. Others argue that the provisions aimed at improving patient safety are critical for addressing the ongoing opioid epidemic. The bill's emergency clause, which allows for immediate enactment upon passage, also highlights the urgency felt by lawmakers to address these pressing public health issues.
Physicians assistants; Pharmacy Act; prescriptions for controlled dangerous substances; Physician Assistant Act; Committee; members; requirements; Public Health Code; authority for physician assistants to carry out certain functions; prescribing and administering controlled substances; supervision.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.